[ALKS] Alkermes plc

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 57.99 Change: 1.68 (2.98%)
Ext. hours: Change: 0 (0%)

chart ALKS

Refresh chart

Strongest Trends Summary For ALKS

ALKS is in the long-term down -59% in 2 years and down -74% below S&P in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; VIVITROL for alcohol and opioid dependence; TRICOR, LIPANTHYL, LIPIDIL, and SUPRALIP to lower cholesterol; ZANAFLEX for muscle spasticity; AVINZA for moderate to severe pain; EMEND to treat nausea associated with chemotherapy and surgery; and FOCALIN XR and RITALIN LA for attention deficit and hyperactivity disorder. Its products also include MEGACE ES to treat cachexia associated with AIDS; LUVOX CR for obsessive-compulsive disorder; RAPAMUNE to prevent renal transplant rejection; NAPRELAN for mild to moderate pain indications; VERAPAMIL SR, VERELAN, VERELAN PM, VERAPAMIL PM, VERECAPS, UNIVER, and AFEDlTAB CR for hypertension; DILZEM SR, DILZEM XL, DILTELAN, and CARDIZEM CD for hypertension a

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-1.31 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 5.08% Sales Growth - Q/Q-7.96% P/E-43.63
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-1.89% ROE-2.56% ROI-2.04%
Current Ratio8.79 Quick Ratio8.36 Long Term Debt/Equity0.39 Debt Ratio0.08
Gross Margin72.77% Operating Margin-15.17% Net Profit Margin-5.6% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities17.94 M Cash From Investing Activities-31.78 M Cash From Operating Activities-13.33 M Gross Profit120.95 M
Net Profit-46.11 M Operating Profit-52.52 M Total Assets1.91 B Total Current Assets1.02 B
Total Current Liabilities134.22 M Total Debt354.81 M Total Liabilities515.68 M Total Revenue151.37 M
Technical Data
High 52 week61.63 Low 52 week24.85 Last close24.85 Last change-1.78%
RSI9.78 Average true range1.04 Beta1.3 Volume502.8 K
Simple moving average 20 days-13.22% Simple moving average 50 days-22.94% Simple moving average 200 days-36.99%
Performance Data
Performance Week-5.51% Performance Month-25.06% Performance Quart-31.73% Performance Half-44.17%
Performance Year-57.8% Performance Year-to-date-29.22% Volatility daily3.38% Volatility weekly7.57%
Volatility monthly15.51% Volatility yearly53.73% Relative Volume195.73% Average Volume1.08 M
New High New Low

News

2019-11-19 09:36:02 | Alkermes to Acquire Rodin Therapeutics, Boost CNS Pipeline

2019-11-19 09:26:02 | Protalix Finalizes Accelerated Approval Pathway for PRX-102

2019-11-19 07:00:00 | Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder

2019-11-18 17:25:10 | Celgene's Revlimid-Rituximab Combo Gets Positive CHMP Opinion

2019-11-18 08:22:58 | Struggling drugmaker Alkermes buys Boston biotech

2019-11-18 07:30:00 | Alkermes to acquire Rodin Therapeutics for up to $950 million

2019-11-18 07:00:00 | Alkermes to Acquire Rodin Therapeutics

2019-11-15 10:02:03 | VistaGen's VTGN Major Depressive Disorder Drug Disappoints

2019-11-15 08:57:01 | Sarepta SRPT Stock Down Despite New $48M Gene Therapy Deal

2019-11-14 15:08:00 | Biogen shares fall 3%

2019-11-14 10:20:03 | BioDelivery BDSI Stock Up on Q3 Earnings Beat & Raised View

2019-11-13 09:23:02 | Top Ranked Momentum Stocks to Buy for November 13th

2019-11-13 09:05:02 | Catalyst's CPRX Q3 Earnings Beat Estimates, Sales Miss

2019-11-13 08:00:01 | IVERIC bio ISEE Q3 Loss Narrows Y/Y, Zimura Advancing Well

2019-11-12 16:01:00 | Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences

2019-11-12 09:52:02 | Amicus' FOLD Shares Rise on Q3 Earnings & Revenue Beat

2019-11-12 07:00:00 | Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY™

2019-11-08 14:33:07 | Sarepta SRPT Q3 Loss Widens Y/Y, Revenues Beat Estimates

2019-11-08 10:08:03 | Spectrum Pharma's SPPI Q3 Loss Narrows, Focus on Rolontis

2019-11-08 10:00:03 | Global Blood's GBT Q3 Loss Widens, Voxelotor in Focus

2019-11-08 09:32:02 | Clovis CLVS Q3 Earnings & Sales Beat Estimates, Shares Up

2019-11-08 08:56:01 | Arena Pharmaceuticals' ARNA Q3 Loss Widens, Revenues Beat

2019-11-08 08:14:09 | The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut

2019-11-08 07:00:00 | Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's SITC 34th Annual Meeting

2019-11-07 14:30:37 | 7 Stocks the Vanguard Health Care Fund Keeps Buying

2019-11-07 11:53:18 | Biotech Stock On The Radar: Alkermes At A Crossroads

2019-11-07 11:08:04 | Zoetis ZTS Beats on Earnings in Q3, Reports In-Line Sales

2019-11-07 11:05:04 | Horizon Therapeutics' HZNP Q3 Earnings Beat Estimates

2019-11-07 10:47:03 | Zacks.com featured highlights include: Qualys, Fortinet, Zumiez, Commvault Systems and Alkermes

2019-11-06 08:13:01 | Check 5 Best Liquid Stocks for Impressive Returns

2019-11-04 07:00:00 | Alkermes to Present Data From ALKS 4230 Clinical Development Program at the Society for Immunotherapy of Cancer's SITC 34th Annual Meeting

2019-11-03 10:51:51 | The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight

2019-10-30 10:34:00 | Biogen’s Alzheimer’s Drug Could Be a Winner. One Analyst Recommends the Bet.

2019-10-30 08:03:50 | UPDATE 2-Small relief for Biogen in MS drug approval

2019-10-30 07:40:00 | Biogen's and Alkermes' Vumerity gets FDA approval for MS; Biogen's stock surges

2019-10-30 07:30:05 | Biogen and Alkermes Announce FDA Approval of VUMERITY™ diroximel fumarate for Multiple Sclerosis

2019-10-29 11:10:03 | Incyte INCY Beats on Q3 Earnings & Sales, Ups Jakafi View

2019-10-29 09:00:01 | All You Need to Know About Alkermes ALKS Rating Upgrade to Strong Buy

2019-10-24 11:09:42 | Is Alkermes Plc ALKS Going To Burn These Hedge Funds ?

2019-10-24 10:06:02 | Alkermes' ALKS Earnings and Sales Beat Estimates in Q3

2019-10-24 07:17:07 | How Many Alkermes plc NASDAQ:ALKS Shares Did Insiders Buy, In The Last Year?

2019-10-23 22:45:15 | Edited Transcript of ALKS earnings conference call or presentation 23-Oct-19 12:00pm GMT

2019-10-23 14:29:05 | Drugmaker Alkermes cuts 160 jobs in effort to lower expenses

2019-10-23 08:25:12 | Alkermes ALKS Reports Q3 Loss, Tops Revenue Estimates

2019-10-23 07:00:00 | Alkermes Plc Reports Third Quarter 2019 Financial Results and Implementation of Restructuring

2019-10-22 11:32:03 | Drug/Biotech Stock Q3 Earnings on Oct 23: LLY, ALXN & More

2019-10-21 07:00:00 | Alkermes Announces Clinical Collaboration With Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230

2019-10-16 16:01:00 | Alkermes to Host Conference Call to Discuss Third Quarter 2019 Financial Results

2019-10-08 08:33:12 | Biogen Strengthens MS & SMA Portfolio as Competition Lurks

2019-10-07 07:00:00 | Alkermes Presents New Health Economics and Outcomes Research on Patients With Schizophrenia and Bipolar I Disorder at 2019 Psych Congress